There is no confirmed date for Foundayo (orforglipron) becoming available on the NHS. Its UK marketing authorisation, granted on 10 August 2026, allows it to be prescribed in principle, but NHS funding is a separate decision made by NICE — and no NICE timetable has been published.
If you're weighing up your options, this article explains exactly what the licence does and doesn't mean, how NHS funding for weight-loss medicines is decided, and what routes exist in the meantime. For a factual reference on the medicine itself, see our Foundayo page.
The short answer
A medicine reaching the NHS involves two separate hurdles. The first is a licence (a marketing authorisation) from the MHRA, which confirms the medicine meets standards of quality, safety and effectiveness. Foundayo cleared this hurdle on 10 August 2026 — the first approval of this GLP-1 tablet in Europe.
The second hurdle is NHS funding, which in England is guided by an appraisal from the National Institute for Health and Care Excellence (NICE). That process assesses whether a medicine is cost-effective for the NHS. For Foundayo, no NICE appraisal outcome and no funding date have been confirmed.
So: a licence exists; NHS availability does not yet. Authorisation is not the same as availability.
Why a licence doesn't mean NHS access
It's a common assumption that once a medicine is approved, the NHS will simply start prescribing it. In reality, the MHRA and NICE do different jobs.
- The MHRA decides whether a medicine can legally be sold and prescribed in the UK at all.
- NICE (and the NHS bodies that act on its guidance) decides whether the NHS will routinely pay for it, for which patients, and under what conditions.
These decisions can be months or years apart, and NICE can recommend a medicine only for a specific subgroup rather than everyone who is eligible for it in principle. This is exactly what happened with earlier weight-management medicines, where NHS access was narrower than the licence and often routed through specialist weight-management services.
What we know about Foundayo's UK status
Here are the confirmed facts, and the important caveats:
- Foundayo (orforglipron) received FDA approval on 1 April 2026 and an MHRA marketing authorisation on 10 August 2026, for weight management and type 2 diabetes.
- It is a small-molecule (non-peptide) GLP-1 tablet — the first of that specific kind, and the first designed to be taken at any time of day, with or without food or water. It is not the first oral GLP-1 in general: oral semaglutide came first, and the Wegovy Tablet we supply is also a GLP-1 you swallow.
- NHS funding is a separate NICE decision. No date is confirmed, and there is no published UK price.
Because it is a prescription-only medicine, we're not able to advertise it or make product claims about it to the public. This article is factual background only.
How NHS funding for weight-loss medicines is decided
When NICE appraises a new medicine, it typically weighs how well it works, how it compares with existing treatments, its impact on quality of life, and its cost relative to the health benefits it delivers. It may then recommend the medicine, recommend it only for certain patients, or not recommend it for routine NHS use.
Even after a positive NICE recommendation, there can be a further wait while NHS services set up prescribing pathways. For weight-management medicines specifically, NHS access has historically been prioritised for people with a higher BMI and weight-related health conditions, often via specialist services rather than a routine GP appointment.
All of this means that predicting a date — for Foundayo or any newly licensed medicine — isn't possible until NICE publishes its own timetable and decision.
Who is eligible for weight-loss treatment in principle?
Whether through the NHS or a private clinic, prescribing for weight management generally follows the same clinical eligibility framework. You may be considered if you are:
- aged 18 or over;
- living with a BMI of 30 or above (obesity), or
- a BMI of 27–30 with a weight-related condition such as type 2 diabetes, high blood pressure or sleep apnoea.
These medicines are not suitable for everyone. They are generally not prescribed if you are pregnant, planning pregnancy or breastfeeding; have type 1 diabetes; have a personal or family history of medullary thyroid cancer or MEN2; have a history of pancreatitis; have severe gastrointestinal disease; have an active eating disorder; have severe liver or kidney impairment; or are allergic to the active ingredient. A prescriber checks all of this before any treatment is considered.
What are your options while there's no NHS date?
Because no NHS route for Foundayo is confirmed, some people look at licensed, in-stock alternatives that a regulated pharmacy can supply now after a consultation. Our position on Foundayo is straightforward: we do not supply it yet, and we intend to offer it once we are able to obtain it.
In the meantime, other MHRA-licensed weight-management medicines are available privately:
| Medicine | Type | From (per month) |
|---|---|---|
| Mounjaro (tirzepatide) | Weekly injection (GLP-1 and GIP) | £160 |
| Wegovy injection (semaglutide) | Weekly injection (GLP-1) | £115 |
| Wegovy Tablet (oral semaglutide) | Once-daily tablet (GLP-1) | £115 |
The Wegovy Tablet is taken first thing on an empty stomach with a small sip of plain water, then you wait at least 30 minutes before eating, drinking anything else or taking other medicines — taken with food it is far less effective. You can compare all options on our treatments overview or the weight-loss injections page.
What to expect from these medicines
GLP-1 based medicines work by mimicking a natural gut hormone that helps control appetite, so you feel fuller sooner and for longer. In the Phase 3 ATTAIN-1 trial, participants on the 36mg dose of orforglipron lost on average 12.4% of their body weight over 72 weeks, alongside lifestyle counselling. Individual results vary; not everyone reaches this.
The most common side effects across this class include nausea, diarrhoea, constipation, vomiting, decreased appetite and fatigue. Rare but serious risks include severe allergic reactions and acute pancreatitis. If you experience side effects from any medicine, you can report them via the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk/.
How to check whether treatment is right for you
All of these are prescription-only medicines, available only after a clinical consultation with a GPhC-registered prescriber. Treatment is prescribed only if it is clinically appropriate and safe for you — it is never guaranteed.
If you'd like to understand your options, the free online consultation checks your eligibility and lets a registered prescriber review your health. You only pay if a treatment is prescribed and you choose to proceed. You can also learn more about The Weight Clinic or contact us with questions.
This article is for information only and is not a substitute for personalised medical advice. Weight-loss medicines are prescription-only, are not suitable for everyone, and are prescribed only after a clinical consultation with a GPhC-registered prescriber. Individual results vary. Always speak to a UK-registered pharmacist or doctor before starting or changing any prescription medication.
